• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Integra LifeSciences Holdings Corporation

    5/30/25 4:44:55 PM ET
    $IART
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email
    SD 1 iart-formsdconflictmineral.htm SD Document

    United States
    Securities and Exchange Commission
    Washington, D.C. 20549
     
    FORM SD
     
     
    Specialized Disclosure Report
     
     
    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware 000-26224 51-0317849
    (State or other jurisdiction
    of incorporation or organization)
     
    Commission
    File Number
     
    (I.R.S. Employer
    Identification No.)
    1100 CAMPUS ROAD
    PRINCETON, NEW JERSEY 08540
    (Address of principal executive offices)
     
    Lesha Shinn
    Vice President, Deputy General Counsel & Secretary 
    (609) 275-0500
    (Name and telephone number, including area code, of the person to contact in connection with this report)
     
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
     
    x
    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024
     
     
     






    Section 1 — Conflict Minerals Disclosure
    Item 1.01 Conflict Minerals Disclosure
    This Form SD of Integra LifeSciences Holdings Corporation (the “Company”) has been prepared and filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2024 to December 31, 2024 (the “Reporting Period”).
    A copy of the Company’s conflict minerals report prepared in accordance with the Rule for the Reporting Period is attached as Exhibit 1.01 to this Form SD and is also available at the following internet website https://www.integralife.com/ConflictMineralsPolicy.
    The reference to Integra’s website is provided for convenience only, and its contents are not incorporated by reference into this Form SD and the conflict minerals report nor deemed filed with the U.S. Securities and Exchange Commission.
    Item 1.02 Exhibit
    The Company has filed, as Exhibit 1.01 to this Form SD, the conflict minerals report required by Item 1.01.
    Section 2 — Exhibits
    Item 2.01 Exhibits
    The following exhibit is filed as part of this report:
    Exhibit 1.01 — Conflict Minerals Report






    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     

     
    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    Date: May 30, 2025By:/s/ Lea Knight                                 
    Lea Knight
    Title:
    Executive Vice President and Chief Financial Officer


    Get the next $IART alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IART

    DatePrice TargetRatingAnalyst
    3/31/2025Hold → Buy
    Argus
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    10/7/2024Sell → Neutral
    BTIG Research
    7/30/2024$22.00Neutral → Sell
    BTIG Research
    7/30/2024$30.00 → $23.00Neutral → Sell
    Citigroup
    5/7/2024Outperform → Perform
    Oppenheimer
    5/7/2024$45.00 → $25.00Overweight → Equal Weight
    Wells Fargo
    4/3/2024$38.00Sell → Neutral
    Citigroup
    More analyst ratings

    $IART
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

      SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 5:20:30 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

      SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 12:54:20 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

      SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      8/12/24 10:06:35 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Financials

    Live finance-specific insights

    See more
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

      PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conf

      4/18/25 4:30:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance

      PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023. Full-Year 2024 Reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and

      2/25/25 6:00:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Integra upgraded by Argus

      Argus upgraded Integra from Hold to Buy

      3/31/25 8:28:08 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Integra with a new price target

      Morgan Stanley initiated coverage of Integra with a rating of Underweight and set a new price target of $20.00 from $25.00 previously

      12/2/24 8:17:21 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra upgraded by BTIG Research

      BTIG Research upgraded Integra from Sell to Neutral

      10/7/24 7:56:40 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bradley Keith covered exercise/tax liability with 392 shares and was granted 19,592 shares, increasing direct ownership by 27% to 89,136 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/13/25 4:21:57 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Director Graves Jeffrey A was granted 19,592 shares, increasing direct ownership by 157% to 32,086 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/13/25 4:21:16 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Director Clay Shaundra was granted 19,592 shares, increasing direct ownership by 89% to 41,515 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/13/25 4:20:33 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025

      PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conf

      4/18/25 4:30:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

      PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance pati

      3/13/25 5:00:00 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    SEC Filings

    See more
    • SEC Form SD filed by Integra LifeSciences Holdings Corporation

      SD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      5/30/25 4:44:55 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      5/13/25 4:45:09 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Integra LifeSciences Holdings Corporation

      SCHEDULE 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      5/9/25 2:16:33 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/24/24 4:08:19 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/22/24 4:09:18 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    Leadership Updates

    Live Leadership Updates

    See more
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

      PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman. "The board and I are thrilled to welcome Mojdeh as Integra's next president and CEO," sa

      11/4/24 6:00:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

      Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de

      10/1/24 8:30:00 AM ET
      $APRE
      $IART
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)